Drugs / THRV-1268
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07186946 | Sep → Oct 2025 | heart failure | Thryv Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06507839 | May → Nov 2024 | atrial fibrillation | Thryv Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07277582 | Mar 2026 → Jun 2027 expected | long QT syndrome 2 | Thryv Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THRV-1268 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07186946 ↗ |
| Action | Inhibit | “(SGK-1) inhibitor” NCT06507839 ↗ |
| Route | Oral | “5 dosing cohorts will receive a single oral dose of THRV-1268.” NCT06507839 ↗ |
| Target | SGK1 | “THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor” NCT06507839 ↗ |